We present a case of a tenosynovial giant cell tumor (TGCT) incidentally discovered at the shoulder on PET/CT, in a patient with history of thyroid cancer. Many documented cases of TGCT have been incidentally imaged by PET/CT and have been found to have varying levels of metabolic activity, however the shoulder location is unusual. This type of musculoskeletal lesion often has MRI characteristics, such as gradient echo blooming, which can render a confident diagnosis without need for biopsy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030548PMC
http://dx.doi.org/10.1016/j.radcr.2018.02.006DOI Listing

Publication Analysis

Top Keywords

shoulder pet/ct
8
tenosynovial giant
8
giant cell
8
cell tumor
8
tgct incidentally
8
hot shoulder
4
pet/ct lesion
4
lesion unusual
4
unusual presentation
4
presentation tenosynovial
4

Similar Publications

Quantitative analysis of patient motion in walk-through PET scanner and standard axial field of view pet scanner using infrared-based tracking.

EJNMMI Phys

November 2024

Department of Electronics and Information Systems, Medical Image and Signal Processing, Ghent University, C. Heymanslaan 10, Ghent, Belgium.

Background: Long-axial field-of-view (LAFOV) Positron Emission Tomography (PET) scanners provide high sensitivity, but throughput is limited because of time-consuming patient positioning. To enhance throughput, a novel Walk-Through PET (WT-PET) scanner has been developed, allowing patients to stand upright, supported by an adjustable headrest and hand supports. This study evaluates the degree of motion in the WT-PET system and compares it with the standard PET-CT.

View Article and Find Full Text PDF

Case Report: All that glitters is not cancer; perihepatic hibernoma with fluctuating FDG uptake on PET/CT.

Front Nucl Med

October 2024

Radiology Department, The Christie, NHS Foundation Trust, Manchester, United Kingdom.

Hibernomas are rare brown fat tumors that garnered attention in the literature with the increasing use of [F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ([F] FDG PET/CT) for the staging workup and follow-up of solid malignancies. Despite being benign tumors, they exhibit high metabolic activity due to their thermogenic nature, leading to significant radiotracer uptake on functional imaging. This can pose a challenge in differentiating them from the malignant lesions, especially the fat-containing malignancies such as liposarcoma.

View Article and Find Full Text PDF

Case Report: A case of primary pericardial mesothelioma treated with multimodal combined therapy.

Front Cardiovasc Med

October 2024

Department of Radiation Oncology, Shidong Hospital, Yangpu District, Shanghai, China.

Background: Primary pericardial mesothelioma (PMPM) is a rare, aggressive, and lethal form of cancer. Due to its rarity, low incidence and poor prognosis, PMPM has no accepted standard-of-care treatment options with management and outcomes often extrapolated from diffuse pleural mesothelioma. Disease-specific studies are needed to better define PMPM.

View Article and Find Full Text PDF

Preclinical evaluation of Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy.

Eur J Nucl Med Mol Imaging

January 2025

Department of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.

Article Synopsis
  • A new derivative of minigastrin, DOTA-CCK-66, shows promising results in imaging and therapy for medullary thyroid carcinoma (MTC) when labeled with either Gallium (Ga) or Actinium (Ac).
  • In a study using tumor-bearing mice, treatment with either Lu- or Ac-labeled DOTA-CCK-66 significantly reduced tumor growth and increased survival times compared to a control group treated with Ga-labeled DOTA-CCK-66.
  • The Ac-labeled treatment resulted in the highest mean survival rate, indicating its strong therapeutic potential for MTC in future patient management.
View Article and Find Full Text PDF

Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine.

Oncologist

December 2024

Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz - Barmherzige Schwestern Site, Seilerstaette 4, 4020 Linz,Austria.

Background: Biliary tract cancers (BTCs) are a diverse group of malignancies with varied genetic backgrounds. The prevalence of intrahepatic cholangiocarcinoma (iCC) is increasing, particularly in Western countries. Despite advancements in treatments, the prognosis for BTC remains poor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!